应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01672 歌礼制药-B
交易中 04-19 11:30:32
1.230
-0.040
-3.15%
最高
1.270
最低
1.220
成交量
33.30万
今开
1.250
昨收
1.270
日振幅
3.94%
总市值
12.46亿
流通市值
12.46亿
总股本
10.13亿
成交额
41.09万
换手率
0.03%
流通股本
10.13亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
杰富瑞:歌礼制药给予目标价3.8港元 管线取得重大进展
新浪港股 · 10:08
杰富瑞:歌礼制药给予目标价3.8港元 管线取得重大进展
【东北医药刘宇腾】歌礼制药-B(01672)动态点评:亏损同比大幅收窄,关注多里程碑事件催化
东北证券研究所 · 04-16
【东北医药刘宇腾】歌礼制药-B(01672)动态点评:亏损同比大幅收窄,关注多里程碑事件催化
歌礼制药-B盘中异动 股价大跌6.00%
自选股智能写手 · 04-12
歌礼制药-B盘中异动 股价大跌6.00%
歌礼制药-B(01672)股价下跌5.185%,现价港币$1.28
阿斯达克财经 · 04-12
歌礼制药-B(01672)股价下跌5.185%,现价港币$1.28
歌礼制药-B(01672)上涨5.3%,报1.39元/股
金融界 · 04-08
歌礼制药-B(01672)上涨5.3%,报1.39元/股
歌礼制药-B盘中异动 股价大涨5.98%
自选股智能写手 · 04-08
歌礼制药-B盘中异动 股价大涨5.98%
歌礼制药-B(01672)股价上升5.303%,现价港币$1.39
阿斯达克财经 · 04-08
歌礼制药-B(01672)股价上升5.303%,现价港币$1.39
歌礼制药-B盘中异动 早盘股价大跌5.26%报1.280港元
自选股智能写手 · 04-05
歌礼制药-B盘中异动 早盘股价大跌5.26%报1.280港元
歌礼制药-B(01672)股价下跌5.185%,现价港币$1.28
阿斯达克财经 · 04-05
歌礼制药-B(01672)股价下跌5.185%,现价港币$1.28
歌礼孤注一掷NASH
医药魔方 · 04-04
歌礼孤注一掷NASH
歌礼制药又砍研发管线了,18A第一股一败再败
界面 · 04-03
歌礼制药又砍研发管线了,18A第一股一败再败
歌礼制药:不再继续开展ASC42治疗PBC临床试验
界面 · 04-03
歌礼制药:不再继续开展ASC42治疗PBC临床试验
歌礼制药-B(01672)宣布有关FXR激动剂ASC42的战略决定
智通财经网 · 04-03
歌礼制药-B(01672)宣布有关FXR激动剂ASC42的战略决定
歌礼制药-B(01672)下跌5.33%,报1.42元/股
金融界 · 03-27
歌礼制药-B(01672)下跌5.33%,报1.42元/股
国元国际:创新药研发取得优异成果,建议积极关注歌礼制药(1672.HK)
权证网 · 03-27
国元国际:创新药研发取得优异成果,建议积极关注歌礼制药(1672.HK)
2024财报|重押NASH管线,歌礼制药能否扭转“无药可卖”局面
华尔街见闻 · 03-27
2024财报|重押NASH管线,歌礼制药能否扭转“无药可卖”局面
歌礼制药-B盘中异动 早盘股价大跌6.00%
自选股智能写手 · 03-27
歌礼制药-B盘中异动 早盘股价大跌6.00%
《公司业绩》歌礼制药(01672.HK)全年亏损收窄至1.45亿人民币
阿斯达克财经 · 03-26
《公司业绩》歌礼制药(01672.HK)全年亏损收窄至1.45亿人民币
歌礼制药-B(01672.HK)年度亏损减少至1.45亿元
港股那点事 · 03-25
歌礼制药-B(01672.HK)年度亏损减少至1.45亿元
歌礼制药-B(01672)发布2023年度业绩,收入约5660万元,同比增加4.6%
智通财经 · 03-25
歌礼制药-B(01672)发布2023年度业绩,收入约5660万元,同比增加4.6%
加载更多
公司概况
公司名称:
歌礼制药-B
所属市场:
SEHK
上市日期:
--
主营业务:
歌礼制药有限公司是一家主要从事生物制品研发的中国公司。该公司主要专注于抗病毒、癌症及脂肪肝疾 病三大治疗领域。该公司的主要产品包括抗丙型肝炎病毒(HCV)、人类免疫缺陷病毒(HIV)及乙型肝炎(HBV)药物。
发行价格:
--
{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":1.23,"timestamp":1713497321057,"preClose":1.27,"halted":0,"volume":333000,"delay":0,"floatShares":1012758000,"shares":1012758000,"eps":-0.1454408,"marketStatus":"交易中","marketStatusCode":2,"change":-0.04,"latestTime":"04-19 11:30:32","open":1.25,"high":1.27,"low":1.22,"amount":410910,"amplitude":0.03937,"askPrice":1.26,"askSize":49000,"bidPrice":1.22,"bidSize":38000,"shortable":0,"etf":0,"ttmEps":-0.145440806100559,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1713499200000},"adr":0,"listingDate":1533052800000,"adjPreClose":1.27,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":1.778656,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"2428574214","title":"杰富瑞:歌礼制药给予目标价3.8港元 管线取得重大进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2428574214","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2428574214?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:08","pubTimestamp":1713492480,"startTime":"0","endTime":"0","summary":" 2024年4月18日,杰富瑞发布的研究报告指出,歌礼制药当前主要聚焦于ASC41和ASC40在NASH适应症领域的应用,并等待ASC40的III期rGBM试验下半年中期结果的揭晓。ASC41在治疗NASH的二期中期数据中展现出积极结果,与已获FDA批准的雷美替罗具有相似性质,并在减少肝脏脂肪方面表现出显著优势。ASC40在F2/F3 NASH和痤疮的临床试验中也取得积极结果。目前,歌礼制药具备充足的现金储备,有能力推进在肝病领域的研发工作,杰富瑞给予其3.8港币的目标价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2024-04-19/doc-inasiqcw7517051.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2024-04-19/doc-inasiqcw7517051.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2427854833","title":"【东北医药刘宇腾】歌礼制药-B(01672)动态点评:亏损同比大幅收窄,关注多里程碑事件催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2427854833","media":"东北证券研究所","top":-1,"share":"https://www.laohu8.com/m/news/2427854833?lang=zh_cn&edition=full","pubTime":"2024-04-16 08:49","pubTimestamp":1713228561,"startTime":"0","endTime":"0","summary":"事件:近日,公司发布2023年年度业绩公告。2023年公司亏损缩窄约54%,主要由于产品销售收入增加、存货管理改善导致销售成本下降以及Sagimet Biosciences于2023年在纳斯达克股票市场首次公开发售产生的摊薄权益收益等其他收入及收益增加。公司聚焦核心管线,NASH/痤疮等多产品取得重大进展。2024年多里程碑事件预计完成,将持续提升公司价值,建议关注相关催化。多临床进度推进及数据公布,推荐关注相关管线催化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160852148b28184e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160852148b28184e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426228379","title":"歌礼制药-B盘中异动 股价大跌6.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426228379","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426228379?lang=zh_cn&edition=full","pubTime":"2024-04-12 11:00","pubTimestamp":1712890812,"startTime":"0","endTime":"0","summary":"2024年04月12日早盘11时00分,歌礼制药-B股票出现波动,股价大幅下挫6.00%。截至发稿,该股报1.270港元/股,成交量38.7万股,换手率0.04%,振幅4.44%。歌礼制药-B股票所在的生物技术行业中,整体跌幅为0.14%。歌礼制药-B公司简介:歌礼制药股份有限公司是一家主要从事医药产品的研发、生产、行销及销售的中国投资控股公司。该公司主要专注于病毒性疾病、非酒精性脂肪性肝炎及肿瘤领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404121100127920106f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404121100127920106f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426225874","title":"歌礼制药-B(01672)股价下跌5.185%,现价港币$1.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2426225874","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426225874?lang=zh_cn&edition=full","pubTime":"2024-04-12 11:00","pubTimestamp":1712890800,"startTime":"0","endTime":"0","summary":"[下跌股]歌礼制药-B(01672) 股价在上午11:00比前收市价下跌5.185%,现股价为港币$1.28。至目前为止,今日最高价为$1.33,而最低价为$1.28。总成交量为23.9万股,总成交金额为港币$31.169万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2404122046/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2425959604","title":"歌礼制药-B(01672)上涨5.3%,报1.39元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425959604","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425959604?lang=zh_cn&edition=full","pubTime":"2024-04-08 15:58","pubTimestamp":1712563103,"startTime":"0","endTime":"0","summary":"4月8日,歌礼制药-B(01672)盘中上涨5.3%,截至15:58,报1.39元/股,成交103.92万元。歌礼制药是一家致力于为抗病毒、癌症和脂肪肝等领域提供创新治疗方案的生物科技公司,覆盖从新药研发到生产和商业化的完整价值链。公司以高度一体化的抗病毒平台为基础,专注于为慢性丙肝、慢性乙肝和艾滋病患者提供创新药物,使其得到可负担的医疗解决方案。截至2023年年报,歌礼制药-B营业总收入5659.6万元、净利润-1.45亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/08155840148369.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425985426","title":"歌礼制药-B盘中异动 股价大涨5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425985426","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425985426?lang=zh_cn&edition=full","pubTime":"2024-04-08 10:55","pubTimestamp":1712544925,"startTime":"0","endTime":"0","summary":"2024年04月08日早盘10时55分,歌礼制药-B股票出现波动,股价快速上涨5.98%。截至发稿,该股报1.400港元/股,成交量3.4万股,换手率0.00%,振幅5.30%。歌礼制药-B股票所在的生物技术行业中,整体涨幅为0.85%。其相关个股中,康宁杰瑞制药-B、泰格医药、华领医药-B涨幅较大,振幅较大的相关个股有康宁杰瑞制药-B、金斯瑞生物科技、科笛-B,振幅分别为14.18%、12.85%、11.83%。该公司主要专注于病毒性疾病、非酒精性脂肪性肝炎及肿瘤领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081055257a51433c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081055257a51433c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425409985","title":"歌礼制药-B(01672)股价上升5.303%,现价港币$1.39","url":"https://stock-news.laohu8.com/highlight/detail?id=2425409985","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2425409985?lang=zh_cn&edition=full","pubTime":"2024-04-08 10:55","pubTimestamp":1712544900,"startTime":"0","endTime":"0","summary":"[上升股]歌礼制药-B(01672) 股价在上午10:55比前收市价上升5.303%,现股价为港币$1.39。至目前为止,今日最高价为$1.39,而最低价为$1.33。总成交量为3.2万股,总成交金额为港币$4.409万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404081517/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2425130876","title":"歌礼制药-B盘中异动 早盘股价大跌5.26%报1.280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425130876","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425130876?lang=zh_cn&edition=full","pubTime":"2024-04-05 10:15","pubTimestamp":1712283309,"startTime":"0","endTime":"0","summary":"2024年04月05日早盘10时15分,歌礼制药-B股票出现波动,股价急速下跌5.26%。截至发稿,该股报1.280港元/股,成交量27.41万股,换手率0.03%,振幅3.70%。资金方面,该股资金流入4.235万港元,流出30.218万港元。歌礼制药-B股票所在的生物技术行业中,整体跌幅为1.38%。该公司主要专注于病毒性疾病、非酒精性脂肪性肝炎及肿瘤领域。消息层面,截至10时15分,《歌礼制药又砍研发管线了,18A第一股一败再败》资讯为影响歌礼制药-B的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404051015117a510d00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404051015117a510d00&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425706303","title":"歌礼制药-B(01672)股价下跌5.185%,现价港币$1.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2425706303","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2425706303?lang=zh_cn&edition=full","pubTime":"2024-04-05 10:15","pubTimestamp":1712283300,"startTime":"0","endTime":"0","summary":"[下跌股]歌礼制药-B(01672) 股价在上午10:15比前收市价下跌5.185%,现股价为港币$1.28。至目前为止,今日最高价为$1.33,而最低价为$1.28。总成交量为27.01万股,总成交金额为港币$35.369万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2404051383/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2424386848","title":"歌礼孤注一掷NASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2424386848","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2424386848?lang=zh_cn&edition=full","pubTime":"2024-04-04 08:43","pubTimestamp":1712191390,"startTime":"0","endTime":"0","summary":"绝地求生下,歌礼制药将削减管线节流而来的资金加注到NASH赛道。2023年6月,歌礼制药宣布终止治疗肝癌的候选药物ASC06和HIV新药ASC09的开发。所以,歌礼制药表示已经在2020年决定不再继续进行ASC06的研发。未来,歌礼制药重点将宝押注在NASH赛道。ASC41治疗经肝穿活检证实的NASH患者的II期临床试验取得了积极结果。今年3月,Madrigal Pharmaceuticals开发的Resmetirom获加速批准上市,成为FDA批准的首个治疗NASH的创新药物。至于歌礼制药能否真正穿越NASH这一研发死亡谷,我们拭目以待。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040408443487dc96e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040408443487dc96e9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424841951","title":"歌礼制药又砍研发管线了,18A第一股一败再败","url":"https://stock-news.laohu8.com/highlight/detail?id=2424841951","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2424841951?lang=zh_cn&edition=full","pubTime":"2024-04-03 22:09","pubTimestamp":1712153379,"startTime":"0","endTime":"0","summary":"该药由此成为FDA批准的首款NASH疗法。目前,歌礼制药的研发管线覆盖病毒性疾病、NASH、肿瘤三大领域。到2023年,歌礼制药已不再积极推广丙肝药产品。此前,歌礼制药于2018年11月与罗氏签订独家合作协议,获得派罗欣在中国大陆地区的独家市场推广权,并有权获得一定比例的销售收入作为对价。歌礼制药预计,这足以支撑公司直到2028年的研发活动和运营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040322113987daf9a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040322113987daf9a1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424994538","title":"歌礼制药:不再继续开展ASC42治疗PBC临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2424994538","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2424994538?lang=zh_cn&edition=full","pubTime":"2024-04-03 17:13","pubTimestamp":1712135602,"startTime":"0","endTime":"0","summary":"歌礼制药4月3日在港交所公告,对ASC42治疗原发性胆汁性胆管炎的II期临床试验数据进行全面分析后,公司做出了不再继续开展ASC42治疗PBC临床试验的战略决定。该决定基于12周II期研究的疗效和安全性数据,该研究包括三个ASC42活性治疗组和一个安慰剂对照组。结果表明,与目前处于开发和注册阶段的新型PBC候选药物相比,ASC42未显示出竞争优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031713227a50ec02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031713227a50ec02&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424895084","title":"歌礼制药-B(01672)宣布有关FXR激动剂ASC42的战略决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2424895084","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2424895084?lang=zh_cn&edition=full","pubTime":"2024-04-03 17:04","pubTimestamp":1712135083,"startTime":"0","endTime":"0","summary":"歌礼制药-B(01672)发布公告,对ASC42治疗原发性胆汁性胆管炎(PBC)的...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_28.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_28.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1098454.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422393164","title":"歌礼制药-B(01672)下跌5.33%,报1.42元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422393164","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422393164?lang=zh_cn&edition=full","pubTime":"2024-03-27 14:21","pubTimestamp":1711520487,"startTime":"0","endTime":"0","summary":"3月27日,歌礼制药-B(01672)盘中下跌5.33%,截至14:21,报1.42元/股,成交114.56万元。歌礼制药是一家致力于为抗病毒、癌症和脂肪肝等领域提供创新治疗方案的生物科技公司,覆盖从新药研发到生产和商业化的完整价值链。公司以高度一体化的抗病毒平台为基础,专注于为慢性丙肝、慢性乙肝和艾滋病患者提供创新药物,使其得到可负担的医疗解决方案。截至2023年年报,歌礼制药-B营业总收入5659.6万元、净利润-1.45亿元。3月25日,2023财年年报归属股东应占溢利-1.447亿人民币,同比增长54.04%,基本每股收益-0.1347人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/27142140012798.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422935387","title":"国元国际:创新药研发取得优异成果,建议积极关注歌礼制药(1672.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422935387","media":"权证网","top":-1,"share":"https://www.laohu8.com/m/news/2422935387?lang=zh_cn&edition=full","pubTime":"2024-03-27 13:34","pubTimestamp":1711517660,"startTime":"0","endTime":"0","summary":"近日,国元国际发布歌礼制药研报,并建议积极关注。研报指出,公司创新药研发取得优异成果,现金储备充足。ASC41NASH的II期期中分析数据12周治疗显著降低肝脂肪及炎症。国元国际认为,公司ASC40治疗痤疮,空间广阔。目前市值仅15亿港元,而且公司注重投资者回报,已经回购注销1.3亿港元股票,公司价值严重低估,建议积极关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032713342787badc7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032713342787badc7b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422871985","title":"2024财报|重押NASH管线,歌礼制药能否扭转“无药可卖”局面","url":"https://stock-news.laohu8.com/highlight/detail?id=2422871985","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2422871985?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:30","pubTimestamp":1711506647,"startTime":"0","endTime":"0","summary":"诉讼风波难解","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/content_default_9.jpg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/content_default_9.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3711414","is_publish_highlight":false,"gpt_icon":0},{"id":"2422601986","title":"歌礼制药-B盘中异动 早盘股价大跌6.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422601986","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422601986?lang=zh_cn&edition=full","pubTime":"2024-03-27 09:37","pubTimestamp":1711503470,"startTime":"0","endTime":"0","summary":"2024年03月27日早盘09时37分,歌礼制药-B股票出现异动,股价大幅下跌6.00%。截至发稿,该股报1.410港元/股,成交量23.6万股,换手率0.02%,振幅6.00%。歌礼制药-B股票所在的生物技术行业中,整体跌幅为0.40%。消息层面,截至09时37分,《歌礼制药-B发布2023年度业绩,收入约5660万元,同比增加4.6%》资讯为影响歌礼制药-B的重要信息。截至2023年12月31日,集团的现金及现金等价物以及定期存款约为22.746亿元,其预计足以支持其直至2028年的研发活动及营运。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032709375187e7bf6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032709375187e7bf6a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422528313","title":"《公司业绩》歌礼制药(01672.HK)全年亏损收窄至1.45亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2422528313","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422528313?lang=zh_cn&edition=full","pubTime":"2024-03-26 00:22","pubTimestamp":1711383720,"startTime":"0","endTime":"0","summary":"歌礼制药-B(01672.HK) 公布2023年止年度业绩,收入录得5,660万人民币(下同),按年增加4.6%。亏损由上年度3.15亿元,收窄至1.45亿元,每股亏损13.47分。不派末期息。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2023/08/22中期业绩无派息2023/03/20末期业绩无派息 2022/08/22中期业绩无派息 2022/03/22末期业绩无派息 AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200428112816451_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200428112816451_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1336777/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422172175","title":"歌礼制药-B(01672.HK)年度亏损减少至1.45亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422172175","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2422172175?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:27","pubTimestamp":1711373247,"startTime":"0","endTime":"0","summary":"格隆汇3月25日丨歌礼制药-B公告,截至2023年12月31日止年度,公司收入由上年度的约人民币54.1百万元增加4.6%至约人民币56.6百万元。集团的总收入由上年度的约人民币166.1百万元增加45.2%至约人民币241.2百万元。集团的研发成本由上年度的约人民币267.1百万元减少18.8%至该年度的约人民币216.8百万元,主要由于临床及临床前项目研发效率提高;及无形资产的折旧及摊销成本减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-25/doc-inappxsk1430773.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-25/doc-inappxsk1430773.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422512713","title":"歌礼制药-B(01672)发布2023年度业绩,收入约5660万元,同比增加4.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422512713","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422512713?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:15","pubTimestamp":1711372553,"startTime":"0","endTime":"0","summary":"智通财经APP讯,歌礼制药-B 发布截至2023年12月31日止年度业绩,集团的收入由2022年度的约5410万元增加4.6%至2023年度的约5660万元,乃由于利托那韦产品产生的收入增加约4940万元,但大部分被推广服务收入减少约4040万元所抵销,原因为集团终止向上海罗氏制药有限公司提供派罗欣在中国的推广服务。截至2023年12月31日,集团的现金及现金等价物以及定期存款约为22.746亿元,其预计足以支持其直至2028年的研发活动及营运。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1091816.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":-0.0593},{"period":"1month","weight":-0.2063},{"period":"3month","weight":-0.1645},{"period":"6month","weight":-0.2825},{"period":"1year","weight":-0.5348},{"period":"ytd","weight":-0.1301}],"compareEarnings":[{"period":"1week","weight":-0.0415},{"period":"1month","weight":-0.0087},{"period":"3month","weight":0.0704},{"period":"6month","weight":-0.0458},{"period":"1year","weight":-0.1955},{"period":"ytd","weight":-0.0388}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事生物制品研发的中国公司。该公司主要专注于抗病毒、癌症及脂肪肝疾 病三大治疗领域。该公司的主要产品包括抗丙型肝炎病毒(HCV)、人类免疫缺陷病毒(HIV)及乙型肝炎(HBV)药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.102992},{"month":2,"riseRate":0.666667,"avgChangeRate":0.004802},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.105976},{"month":4,"riseRate":0.5,"avgChangeRate":-0.036964},{"month":5,"riseRate":0.4,"avgChangeRate":-0.017072},{"month":6,"riseRate":0.4,"avgChangeRate":-0.002776},{"month":7,"riseRate":0.4,"avgChangeRate":-0.074118},{"month":8,"riseRate":0.2,"avgChangeRate":-0.0588},{"month":9,"riseRate":0,"avgChangeRate":-0.108951},{"month":10,"riseRate":0.5,"avgChangeRate":-0.070866},{"month":11,"riseRate":0.833333,"avgChangeRate":0.149725},{"month":12,"riseRate":0.5,"avgChangeRate":-0.003643}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}